Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Foloppe

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Journal of Medicinal Chemistry|June 25, 2005
Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinityNicolas Foloppe, Lisa M Fisher, Rob Howes, et al.
Bioorganic & Medicinal Chemistry Letters|June 13, 2009
Discovery and functional evaluation of diverse novel human CB(1) receptor ligandsNicolas Foloppe, Karen Benwell, Teresa D Brooks, et al.
Bioorganic & Medicinal Chemistry|May 1, 2010
Virtual screening, selection and development of a benzindolone structural scaffold for inhibition of lumazine synthaseArindam Talukdar, Ekaterina Morgunova, Jianxin Duan, et al.
Journal of the American Chemical Society|May 7, 2013
Quantum mechanics/molecular mechanics modeling of regioselectivity of drug metabolism in cytochrome P450 2C9Richard Lonsdale, Kerensa T Houghton, Jolanta Żurek, et al.
Plos Computational Biology|April 12, 2014
rDock: a fast, versatile and open source program for docking ligands to proteins and nucleic acidsSergio Ruiz-Carmona, Daniel Alvarez-Garcia, Nicolas Foloppe, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2007
Discovery of a novel class of selective human CB1 inverse agonistsNicolas Foloppe, Nicola H Allen, Carol H Bentley, et al.
Oncotarget|October 6, 2015
Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug designAndrew J Massey, Stephen Stokes, Helen Browne, et al.
Molecular Microbiology|September 14, 2012
Mycoredoxin-1 is one of the missing links in the oxidative stress defence mechanism of MycobacteriaKoen Van Laer, Lieven Buts, Nicolas Foloppe, et al.
Journal of Medicinal Chemistry|June 18, 2021
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1BDavid Lee Walmsley, James B Murray, Pawel Dokurno, et al.
Journal of Medicinal Chemistry|May 12, 2021
Structure-Guided Discovery of Potent and Selective DYRK1A InhibitorsCsaba Weber, Melinda Sipos, Attila Paczal, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Journal of Medicinal Chemistry|June 25, 2005
Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinityNicolas Foloppe, Lisa M Fisher, Rob Howes, et al.
Bioorganic & Medicinal Chemistry Letters|June 13, 2009
Discovery and functional evaluation of diverse novel human CB(1) receptor ligandsNicolas Foloppe, Karen Benwell, Teresa D Brooks, et al.
Bioorganic & Medicinal Chemistry|May 1, 2010
Virtual screening, selection and development of a benzindolone structural scaffold for inhibition of lumazine synthaseArindam Talukdar, Ekaterina Morgunova, Jianxin Duan, et al.
Journal of the American Chemical Society|May 7, 2013
Quantum mechanics/molecular mechanics modeling of regioselectivity of drug metabolism in cytochrome P450 2C9Richard Lonsdale, Kerensa T Houghton, Jolanta Żurek, et al.
Plos Computational Biology|April 12, 2014
rDock: a fast, versatile and open source program for docking ligands to proteins and nucleic acidsSergio Ruiz-Carmona, Daniel Alvarez-Garcia, Nicolas Foloppe, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2007
Discovery of a novel class of selective human CB1 inverse agonistsNicolas Foloppe, Nicola H Allen, Carol H Bentley, et al.
Oncotarget|October 6, 2015
Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug designAndrew J Massey, Stephen Stokes, Helen Browne, et al.
Molecular Microbiology|September 14, 2012
Mycoredoxin-1 is one of the missing links in the oxidative stress defence mechanism of MycobacteriaKoen Van Laer, Lieven Buts, Nicolas Foloppe, et al.
Journal of Medicinal Chemistry|June 18, 2021
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1BDavid Lee Walmsley, James B Murray, Pawel Dokurno, et al.
Journal of Medicinal Chemistry|May 12, 2021
Structure-Guided Discovery of Potent and Selective DYRK1A InhibitorsCsaba Weber, Melinda Sipos, Attila Paczal, et al.
Pageof 6